Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 8Myeloid 3Sarcoma 2Lymphoid 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Myeloid, Chronic-Phase 2

Interventions

Azacitidine 68nilotinib 50Imatinib Mesylate 50ruxolitinib 42Dasatinib 25venetoclax 22Decitabine 20bosutinib 18asciminib 17Cytarabine 15ponatinib 10decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 9fludarabine 8Hydroxyurea 8navitoclax 6ON 01910 6sabatolimab 5pevonedistat 5mocetinostat 5luspatercept 5itacitinib 5imetelstat 5givinostat hydrochloride 5givinostat 5fludarabine phosphate 5avapritinib 5Mycophenolic Acid 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × olverembatinib × Myeloid × Clear all
NCT06423911 2025-06-03

POLARIS-2

Ascentage Pharma Group Inc.

Phase 3 Recruiting
285 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04126681 2025-03-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Ascentage Pharma Group Inc.

Phase 2 Completed
144 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04126707 2021-09-08

The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans

Ascentage Pharma Group Inc.

Phase 1 Completed
6 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡